Open-label, Multicenter, Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS®) in Patients With Chronic Hepatitis D (CHD)
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis D
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 19 Dec 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 21 Feb 2008 New trial record.